U.K. experts have begun an international study to compare a platinum-based drug with standard chemotherapy as a treatment for women with hereditary breast cancer whose disease has returned. The study, which will look at women with faulty BRCA1 or 2 genes, is being conducted in Australia, Europe and the U.S. over the next four years.

Full Story:

Related Summaries